235 related articles for article (PubMed ID: 15173098)
1. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
Park JW; Kerbel RS; Kelloff GJ; Barrett JC; Chabner BA; Parkinson DR; Peck J; Ruddon RW; Sigman CC; Slamon DJ
Clin Cancer Res; 2004 Jun; 10(11):3885-96. PubMed ID: 15173098
[No Abstract] [Full Text] [Related]
2. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
Kelloff GJ; Bast RC; Coffey DS; D'Amico AV; Kerbel RS; Park JW; Ruddon RW; Rustin GJ; Schilsky RL; Sigman CC; Vande Woude GF
Clin Cancer Res; 2004 Jun; 10(11):3881-4. PubMed ID: 15173097
[No Abstract] [Full Text] [Related]
3. Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.
Fine BM; Amler L
Clin Pharmacol Ther; 2009 May; 85(5):535-8. PubMed ID: 19295504
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.
Takimoto CH
Eur J Cancer; 2009 Sep; 45 Suppl 1():436-8. PubMed ID: 19775662
[No Abstract] [Full Text] [Related]
5. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
6. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
7. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
8. Advances and challenges in the use of biomarkers in clinical trials.
Chabner B
Clin Adv Hematol Oncol; 2008 Jan; 6(1):42-3. PubMed ID: 18322440
[No Abstract] [Full Text] [Related]
9. Impact of biomarker usage on oncology drug development.
Hayashi K; Masuda S; Kimura H
J Clin Pharm Ther; 2013 Feb; 38(1):62-7. PubMed ID: 23057528
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in early cancer drug development: limited utility.
Glassman RH; Ratain MJ
Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
Carroll KJ
Pharm Stat; 2007; 6(4):253-60. PubMed ID: 17351904
[TBL] [Abstract][Full Text] [Related]
13. Cancer biomarkers: current issues and future directions.
Jain KK
Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic biomarkers for molecular cancer therapeutics.
Sarker D; Workman P
Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
[TBL] [Abstract][Full Text] [Related]
15. Oncology drug development: what is changing?
Yancey MA
Clin J Oncol Nurs; 2008 Oct; 12(5):713-5. PubMed ID: 18842527
[No Abstract] [Full Text] [Related]
16. BMS and Exelixis target tumor suppression pathways.
Expert Rev Anticancer Ther; 2001 Aug; 1(2):167. PubMed ID: 12113021
[No Abstract] [Full Text] [Related]
17. Discontinued drugs in 2008: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
[TBL] [Abstract][Full Text] [Related]
18. Using biomarkers in drug development.
Workman P
Clin Adv Hematol Oncol; 2006 Oct; 4(10):736-9. PubMed ID: 17099630
[No Abstract] [Full Text] [Related]
19. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
20. Biomarker boom slowed by validation concerns.
Benowitz S
J Natl Cancer Inst; 2004 Sep; 96(18):1356-7. PubMed ID: 15367567
[No Abstract] [Full Text] [Related]
[Next] [New Search]
